Eligibility Sarcoidosis NCT00403650

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00403650

Eligibility Sarcoidosis NCT00403650

  1. StudyEvent: Eligibility
    1. Eligibility Sarcoidosis NCT00403650
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Sarcoidosis
Item
patients with known sarcoidosis 17
boolean
C0036202 (UMLS CUI [1])
Age
Item
age 18 or greater
boolean
C0001779 (UMLS CUI [1])
Pulmonary Hypertension | cardiac catheterization - mean pulmonary artery pressure
Item
patients with documented pulmonary hypertension with a pa mean > 25 mm as measured by cardiac catheterization within six months of entry into the study
boolean
C0020542 (UMLS CUI [1])
C2008312 (UMLS CUI [2])
Dyspnea
Item
patients with dyspnea
boolean
C0013404 (UMLS CUI [1])
6-minute walk test Distance
Item
six minute walk distance of between 100 to 500 meters
boolean
C0430515 (UMLS CUI [1,1])
C0012751 (UMLS CUI [1,2])
Immunotherapy Stable Sarcoidosis | Prednisone | Methotrexate | Azathioprine | Hydroxychloroquine | Cyclophosphamide | Thalidomide | infliximab
Item
patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab
boolean
C0021083 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0036202 (UMLS CUI [1,3])
C0032952 (UMLS CUI [2])
C0025677 (UMLS CUI [3])
C0004482 (UMLS CUI [4])
C0020336 (UMLS CUI [5])
C0010583 (UMLS CUI [6])
C0039736 (UMLS CUI [7])
C0666743 (UMLS CUI [8])
Informed Consent
Item
patients able to provide written consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
pulmonary vasodilators | Flolan | Remodulin | bosentan | sildenafil | Calcium Channel Blockers Dose Stable | Catheterization of right heart
Item
patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker)
boolean
C2143186 (UMLS CUI [1])
C0376357 (UMLS CUI [2])
C1101501 (UMLS CUI [3])
C0252643 (UMLS CUI [4])
C0529793 (UMLS CUI [5])
C0006684 (UMLS CUI [6,1])
C0178602 (UMLS CUI [6,2])
C0205360 (UMLS CUI [6,3])
C0189896 (UMLS CUI [7])
Airway Obstruction Severe | FEV1/FVC percent
Item
patients with severe airway obstruction as defined by fev1/fvc of less than 35%
boolean
C0001883 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0730560 (UMLS CUI [2])
World Health Organization Class Functional
Item
patients with world health organization (who) class iv status
boolean
C0043237 (UMLS CUI [1,1])
C0456387 (UMLS CUI [1,2])
C0205245 (UMLS CUI [1,3])
Pregnancy | Breast Feeding
Item
patients who are pregnant or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Ventricular Dysfunction, Left | Left ventricular ejection fraction
Item
patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%
boolean
C0242698 (UMLS CUI [1])
C0428772 (UMLS CUI [2])
Liver Dysfunction Independent of Sarcoidosis
Item
significant liver dysfunction not due to sarcoidosis
boolean
C0086565 (UMLS CUI [1,1])
C0332291 (UMLS CUI [1,2])
C0036202 (UMLS CUI [1,3])
Organ Disease Severe Impact Survival
Item
patients with severe other organ disease felt by investigators to impact survival during the course of the study
boolean
C0178784 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,3])
C4049986 (UMLS CUI [1,4])
C0038952 (UMLS CUI [1,5])
Inhalation Therapy Quantity Perform Unable
Item
patients unable to perform the 6 inhalation treatments required for therapy
boolean
C0021459 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0884358 (UMLS CUI [1,3])
C1299582 (UMLS CUI [1,4])
Systolic Pressure Systemic
Item
patients with < 90 mm hg systolic systemic blood pressure will be excluded
boolean
C0871470 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])